Market research on the consumer health industry. Our reports feat...
Market research on the consumer health industry. Our reports feature a wealth of standardised and cross-comparable statistics including total market sizes, market share and share data, distribution and industry trends.
There are interesting developments in terms of diverging performances within adult systemic analgesics. In 2023, acetaminophen is set to drive current value growth, and significantly outpace the overall performance of adult analgesics. Growth in…
In the United Arab Emirates, analgesics can be categorised into two groups: products from international brands, and those from regional brands, which tend to be priced lower. By the end of the review period, the majority of analgesics brands were…
While most categories of analgesics are set to witness decreases in retail volume sales over 2023, this is largely due to spikes in sales in the wake of the Coronavirus (COVID-19) pandemic as stress and anxiety levels increased. In 2023, many…
Per capita consumption of analgesics continued to increase in Norway during 2023 after 2022 saw significant increases in consumption of these products. While there was some stockpiling of analgesics seen in Norway during the early stages of the…
Analgesics in Morocco has continued to develop positively in 2023, with total current value sales set to grow at a faster rate than in 2022 and most categories expected to post improved results in volume terms. Together with population growth and…
Analgesics is expected to see a single-digit growth in current value terms in 2023. Sales are benefiting from the stable demand for analgesics and unit price increases linked to rising price lists as a result of the higher cost of production faced by…
The return to normal lifestyles out of the home is driving retail volume and current value sales of analgesics in 2023. Adults and children alike are more exposed to common colds and viruses requiring pain relief. Children in school are no longer…
Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…
Upon the lifting of all COVID-19 related regulations, including the compulsory use of face masks, social distancing rules and compulsory self-isolation, there has been a surge in illness which has been a major contributor to sales growth for…
Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…